KR20070045152A - 항세균 활성을 갖는 신규 화합물 - Google Patents

항세균 활성을 갖는 신규 화합물 Download PDF

Info

Publication number
KR20070045152A
KR20070045152A KR1020067026765A KR20067026765A KR20070045152A KR 20070045152 A KR20070045152 A KR 20070045152A KR 1020067026765 A KR1020067026765 A KR 1020067026765A KR 20067026765 A KR20067026765 A KR 20067026765A KR 20070045152 A KR20070045152 A KR 20070045152A
Authority
KR
South Korea
Prior art keywords
methoxy
methyl
compound
nmr
mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067026765A
Other languages
English (en)
Korean (ko)
Inventor
사바인 삐에라우
글렌 대일
마이클 더블유 카피
코넬리아 줌브런
크리스챤 허브스치웰렌
진-필립페 서리베트
Original Assignee
모르포켐 악티엥게셀샤프트 퓌르 콤비나토리셰 케미
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포켐 악티엥게셀샤프트 퓌르 콤비나토리셰 케미 filed Critical 모르포켐 악티엥게셀샤프트 퓌르 콤비나토리셰 케미
Publication of KR20070045152A publication Critical patent/KR20070045152A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020067026765A 2004-08-25 2005-08-25 항세균 활성을 갖는 신규 화합물 Ceased KR20070045152A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004041163A DE102004041163A1 (de) 2004-08-25 2004-08-25 Neue Verbindungen mit antibakterieller Aktivität
DE102004041163.8 2004-08-25

Publications (1)

Publication Number Publication Date
KR20070045152A true KR20070045152A (ko) 2007-05-02

Family

ID=35431960

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067026765A Ceased KR20070045152A (ko) 2004-08-25 2005-08-25 항세균 활성을 갖는 신규 화합물

Country Status (14)

Country Link
US (1) US20070244103A1 (enExample)
EP (1) EP1781650A1 (enExample)
JP (1) JP2008510762A (enExample)
KR (1) KR20070045152A (enExample)
CN (1) CN101035785A (enExample)
AU (1) AU2005276576A1 (enExample)
BR (1) BRPI0514665A2 (enExample)
CA (1) CA2571132A1 (enExample)
DE (1) DE102004041163A1 (enExample)
IL (1) IL179837A0 (enExample)
MX (1) MX2007002097A (enExample)
NZ (1) NZ552036A (enExample)
RU (1) RU2410386C2 (enExample)
WO (1) WO2006021448A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1796466A4 (en) 2004-06-15 2009-09-02 Glaxo Group Ltd ANTIBACTERIAL AGENTS
JP4887297B2 (ja) * 2004-09-24 2012-02-29 アクテリオン ファーマシューティカルズ リミテッド 新規二環式抗生物質
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
WO2007042325A1 (de) * 2005-10-13 2007-04-19 Morphochem Aktiengesellschaft für kombinatorische Chemie 5-chinolinderivate mit antibakterieller aktivität
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
ATE481406T1 (de) 2006-04-06 2010-10-15 Glaxo Group Ltd Pyrrolochinoxalinonderivate als antibakterielle mittel
GB0608263D0 (en) * 2006-04-26 2006-06-07 Glaxo Group Ltd Compounds
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
TW200819457A (en) 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
CL2007003693A1 (es) 2006-12-22 2008-06-27 Actelion Pharmaceuticals Ltd Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
CL2008001003A1 (es) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
PT2137196E (pt) * 2007-04-20 2010-12-16 Glaxo Group Ltd Compostos tricíclicos contendo azoto como agentes antibacterianos
US8759348B2 (en) * 2007-05-17 2014-06-24 Helperby Therapeutics Limited Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
CA2689102C (en) * 2007-06-15 2016-07-26 Actelion Pharmaceuticals Ltd 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives
JP5323088B2 (ja) 2007-12-18 2013-10-23 アクテリオン ファーマシューティカルズ リミテッド ５−アミノシクリルメチル−オキサゾリジン−２−オン誘導体
EP2080761A1 (en) 2008-01-18 2009-07-22 Glaxo Group Limited Compounds
WO2009097578A1 (en) 2008-02-01 2009-08-06 Takeda Pharmaceutical Company Limited Oxim derivatives as hsp90 inhibitors
BRPI0907892A2 (pt) 2008-02-20 2015-07-28 Actelion Pharmaceuticals Ltd Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
WO2009128019A1 (en) 2008-04-15 2009-10-22 Actelion Pharmaceuticals Ltd Tricyclic antibiotics
JP4833385B1 (ja) 2008-10-07 2011-12-07 アクテリオン ファーマシューティカルズ リミテッド 三環式オキサゾリジノン抗生物質化合物
JP2012505866A (ja) 2008-10-17 2012-03-08 グラクソ グループ リミテッド 抗菌剤として使用される三環式窒素化合物
US8318940B2 (en) 2009-01-15 2012-11-27 Glaxo Group Limited Naphthyridin-2 (1 H)-one compounds useful as antibacterials
US8716280B2 (en) 2009-01-21 2014-05-06 Basilea Pharmaceutica Ag Bicyclic antibiotics
EP2332939A1 (en) 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
JP5697685B2 (ja) 2009-12-18 2015-04-08 バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ 三環式抗生物質
CN103635474B (zh) 2011-06-17 2016-04-27 巴斯利尔药物股份公司 三环抗生素
TW201326180A (zh) 2011-11-30 2013-07-01 Actelion Pharmaceuticals Ltd ３，７－二取代八氫－２Ｈ－吡啶并［４，３－ｅ］［１，３］□嗪－２－酮抗生素
AR090844A1 (es) * 2012-04-27 2014-12-10 Actelion Pharmaceuticals Ltd Proceso para elaborar derivados de naftiridina
CN104803913B (zh) * 2014-01-24 2019-02-12 浙江省化工研究院有限公司 一种碳酸苄基喹啉基酯类化合物、其制备方法及应用
AR101674A1 (es) 2014-08-22 2017-01-04 Glaxosmithkline Ip Dev Ltd Uso de un compuesto tricíclico que contiene nitrógeno
MA41169A (fr) 2014-12-17 2017-10-24 Acraf Composés antibactériens à large spectre d'activité
MA41168A (fr) 2014-12-17 2017-10-24 Acraf Nouveaux composés antibactériens
UY36851A (es) 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas
EP3468975B1 (en) 2016-06-08 2020-04-01 Aziende Chimiche Riunite Angelini Francesco A.C.R. New antibacterial compounds
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
IL299612A (en) 2020-07-02 2023-03-01 Incyte Corp Tricyclic urea compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
CA3211748A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
SMT202500447T1 (it) 2021-11-02 2026-01-12 Flare Therapeutics Inc Agonisti inversi di pparg e loro usi
IL315647A (en) 2022-03-17 2024-11-01 Incyte Corp Tricyclic urea compounds as Jak2 and 617f inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2140417C1 (ru) * 1995-10-17 1999-10-27 Институт физиологически активных веществ РАН Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения
GB0112834D0 (en) * 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
JP4445753B2 (ja) * 2002-01-29 2010-04-07 グラクソ グループ リミテッド アミノピペリジン誘導体
AR040335A1 (es) * 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto
DE10256405A1 (de) * 2002-12-02 2004-06-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen, die Topoisomerase IV inhibieren
DE10247233A1 (de) * 2002-10-10 2004-06-17 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen, die Topoisomerase IV inhibieren
JP4602903B2 (ja) * 2002-10-10 2010-12-22 モルフォケム アクチェンゲゼルシャフト フュア コンビナトリシェ ヘミー 抗菌活性を有する新規化合物
AR042486A1 (es) * 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .

Also Published As

Publication number Publication date
AU2005276576A1 (en) 2006-03-02
MX2007002097A (es) 2007-04-24
DE102004041163A1 (de) 2006-03-02
EP1781650A1 (en) 2007-05-09
BRPI0514665A2 (pt) 2009-03-24
RU2410386C2 (ru) 2011-01-27
CA2571132A1 (en) 2006-03-02
NZ552036A (en) 2010-08-27
CN101035785A (zh) 2007-09-12
RU2007105995A (ru) 2008-10-10
IL179837A0 (en) 2007-05-15
WO2006021448A1 (en) 2006-03-02
US20070244103A1 (en) 2007-10-18
JP2008510762A (ja) 2008-04-10

Similar Documents

Publication Publication Date Title
US20070244103A1 (en) Novel Compounds Having an Anti-Bacterial Activity
RU2397982C2 (ru) Новые соединения с антибактериальным действием
JP4602903B2 (ja) 抗菌活性を有する新規化合物
CA3029202C (en) Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists
CA2903215C (en) Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
JP6948333B2 (ja) Ｒｏｒ−ガンマのモジュレータとしてのベンズイミダゾール誘導体
CZ187395A3 (en) Five-membered heteroaryl-oxazolidinones, their use and medicaments in which said compounds are comprised
KR20100103702A (ko) 축합 아미노디하이드로 티아진 유도체
EP2001478B1 (en) Cyclohexyl or piperidinyl carboxamide antibiotic derivatives
AU2006277662A1 (en) Oxazolidinone-quinolone hybrids as antibacterial compounds
WO2012164085A1 (en) Glycine b antagonists
CN101374831B (zh) 四氢吡喃抗生素
CA2629402C (en) Beta-secretase modulators and methods of use
NZ539217A (en) Bicyclic quinoline derivative compounds having antibacterial activity
MXPA00009837A (en) Pyrazole inhibitors of cytokine production

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20061219

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100810

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120326

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120727

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120326

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I